Alto Neuroscience (NYSE:ANRO) Raised to Hold at Wall Street Zen

Alto Neuroscience (NYSE:ANRO) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Other equities analysts also recently issued research reports about the stock. Wolfe Research initiated coverage on shares of Alto Neuroscience in a research note on Friday, May 22nd. They issued an “outperform” rating on the stock. Robert W. Baird decreased their price target on shares of Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Monday, May 18th. Zacks Research upgraded Alto Neuroscience from a “strong sell” rating to a “hold” rating in a report on Thursday, August 20th. BTIG Research raised their price objective on Alto Neuroscience from $28.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, August 13th. Finally, HC Wainwright boosted their price objective on Alto Neuroscience from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Monday, August 17th. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Alto Neuroscience has a consensus rating of “Moderate Buy” and an average target price of $37.25.

Alto Neuroscience Price Performance

Shares of NYSE:ANRO opened at $35.13 on Friday. The stock has a 50-day simple moving average of $28.78 and a 200-day simple moving average of $24.17. The stock has a market capitalization of $1.38 billion, a P/E ratio of -14.52 and a beta of 1.06. Alto Neuroscience has a 1 year low of $3.41 and a 1 year high of $37.48. The company has a debt-to-equity ratio of 0.07, a quick ratio of 14.85 and a current ratio of 14.85.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.65) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.08. Equities analysts forecast that Alto Neuroscience will post -2.68 earnings per share for the current year.

Institutional Investors Weigh In On Alto Neuroscience

A number of large investors have recently added to or reduced their stakes in ANRO. California State Teachers Retirement System purchased a new stake in Alto Neuroscience during the 2nd quarter worth $251,000. Wellington Management Group LLP boosted its position in Alto Neuroscience by 18.6% in the 2nd quarter. Wellington Management Group LLP now owns 70,913 shares of the company’s stock valued at $1,871,000 after buying an additional 11,114 shares during the last quarter. AWM Investment Company Inc. purchased a new position in Alto Neuroscience in the 2nd quarter valued at about $2,111,000. Bank of New York Mellon Corp acquired a new stake in shares of Alto Neuroscience during the second quarter valued at about $2,014,000. Finally, GK Wealth Management LLC acquired a new stake in shares of Alto Neuroscience during the second quarter valued at about $226,000.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.